Minireviews
Copyright ©The Author(s) 2025.
World J Psychiatry. Jun 19, 2025; 15(6): 105409
Published online Jun 19, 2025. doi: 10.5498/wjp.v15.i6.105409
Table 2 Key findings on the effects based on the positive and negative syndrome scale scores from completed 5-week clinical trials
VariableEMERGENT-1[43]
EMERGENT-2[14]
EMERGENT-3[47]
KarXT vs placebo
P value
KarXT vs placebo
P value
KarXT vs placebo
P value
Number of patients (modified intention-to-treat population)83 vs 87-117 vs 119-114 vs 120-
Least-squares mean change from baseline in PANSS total score (points)-17.4 vs -5.9< 0.001-21.2 vs -11.6< 0.0001-20.6 vs -12.2< 0.0001
Least-squares mean change from baseline in PANSS positive symptom subscore (points)-5.6 vs -2.4< 0.001-6.8 vs -3.9< 0.0001-7.1 vs -3.6< 0.0001
Least-squares mean change from baseline in PANSS negative symptom subscore (points)-3.2 vs -0.9< 0.001-3.4 vs -1.60.0055-2.7 vs -1.80.1224
Least-squares mean change from baseline in PANSS Marder negative symptom subscore (points)-3.9 vs -1.3< 0.001-4.2 vs -2.00.0022-3.5 vs -2.70.1957